Dr. Scott M. Rocklage is a renowned scientist, scholar, and entrepreneur based in Boston. He currently serves as a managing partner of 5 AM Venture Management, a California-based venture capital firm that financed science companies. Scott studied at the University of California, from where he graduated with a BSC in chemistry. He is also Ph.D. holder in Chemistry from the celebrated Massachusetts Institute of Technology. His research project was conducted at a lab named after Richard R. Schrock, a Nobel Prize in Chemistry Winner. Dr. Scott has more than 30 U.S. patents, either invented or co-invented, and over 100 peer-reviewed publications to his name.
Dr. Scott Rocklage boasts of over 30 years of experience in healthcare management. He served the executive director of Cubist Pharmaceuticals from 1994 to 2001 and the founding CEO from 1994 to 2003. He held research and development positions at Salutar and Catalytica Pharmaceuticals. Scott served as the president and CEO at Nycomed Salutar from 1990 to 1994. Between 1992 and 1994, he was the CEO, president, and board chairman at Nycomed Interventional. From 2007 to 2014, he was acting as the Director of Relypsa and Novira Therapeutics.
Dr. Scott’s strategic leadership skills were instrumental in the approval of three drugs, Omniscan, Cubicin, and Teslascan by The Food and Drugs Administration. He was the director of EPIRUS Biopharmaceuticals, Inc. from 2000 to 2004 and Achaogen Inc. from 2014 to 2016. Dr. Scott also served as the executive chairman of Miikana Therapeutics Inc. and Semprus. In 2016, Dr. Scott served briefly as the acting CEO at EPIRUS Biopharmaceuticals.
In 2012, Dr. Scott was appointed as the chairman of Novira Therapeutics, a position he holds to date. Since 2013, he has served as the board chairman at Cidara Therapeutics. Dr. Scott was a board director of Semprus BioSciences Corp. For over ten years now, Scott has served as a director of Pulmatrix, Inc. He joined 5 AM Venture Management in 2003 as a venture partner. A year later, Dr. Scott became a managing partner at the firm, a position he has held up to today. He also serves as a director at MDS Proteomics, a Spanish Biotechnology company.